Edesa Biotech (EDSA) AI Stock Analysis

• Market Cap: $19.03M
• Dividend Yield: N/A
• Average Volume (3M): 93.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: N/A
• EPS Growth: 30.29%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 8,348,161
• 10 Day Avg. Volume: 65,583
• 30 Day Avg. Volume: 93,401
• PEG Ratio: 0.06
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.91
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -68.71
• Enterprise Value/Ebitda: -0.90
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.62
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $1.50 ▲(1.35% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (no revenue, ongoing losses and negative free cash flow) and limited valuation support (negative P/E, no dividend yield provided). Offsetting these risks are a strong positive corporate event (statistically significant Phase 3 mortality benefit) and moderately improving near-term technicals (above 20/50-day averages with RSI in the low-60s).

Positive Factors

Phase 3 efficacy for paridiprubart

A statistically significant mortality reduction in Phase 3 is a durable clinical validation that materially raises the probability of regulatory approval and guideline adoption. This strengthens the company’s development-stage value proposition, supports future commercial uptake in critical care, and can attract partners and payers over the medium term.

Provisional patents and scale-up initiatives

Provisional patents protect intellectual property and create barriers to entry, while government-funded trials and manufacturing scale-up reduce execution risk for commercialization. Together these structural moves improve long-term bargaining power with partners, de-risk launch logistics, and support more durable pathways to market and reimbursement.

Conservative leverage and improved equity base

A near-zero debt position and a materially stronger equity base reduce financial distress risk and give management flexibility to fund trials or negotiate partnerships. Improved capitalization extends operational runway and lowers refinancing pressure, which is a lasting structural advantage for a development-stage biotech.

Negative Factors

No commercial revenue; ongoing losses

The company remains a pure development-stage biotech with no product sales, meaning long-term value depends entirely on successful approval and commercialization of pipeline assets. Continued material net losses create persistent funding needs and prolong the period before positive operating economics can be realized.

Persistent negative operating and free cash flow

Sustained negative operating and free cash flow limits internal funding for trials, manufacturing scale-up, and commercial launch. Even with improvement from prior years, continued cash burn makes the company dependent on external financing, which can dilute existing shareholders and constrain long-term strategic optionality.

Deeply negative returns; reliance on external funding

A very negative ROE signals the company is not generating returns on invested capital and will likely need recurrent capital raises to support operations and commercialization. This structural dependency can impair negotiating leverage with partners and increase execution risk during the critical transition to commercial revenues.

Edesa Biotech Business Overview & Revenue Model

Company Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

How the Company Makes Money

Edesa Biotech generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company earns money by securing funding through public offerings, partnerships, and collaborations with other pharmaceutical and biotechnology firms. These partnerships often involve licensing agreements, where Edesa may receive upfront payments, milestone payments, and royalties based on the commercial success of its products. Additionally, Edesa Biotech may engage in research grants and government funding initiatives as part of its revenue model, leveraging these resources to advance its clinical trials and drug development programs.

Edesa Biotech Financial Statement Overview

Summary

Development-stage profile with no revenue and continued sizable losses (TTM net income and EBITDA about -$7.8M) plus ongoing cash burn (TTM operating cash flow and free cash flow about -$7.9M). Balance sheet risk is lower due to essentially no debt and improved equity, but returns remain deeply negative (TTM ROE around -65%), indicating continued reliance on external funding.

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and continued heavy losses (net income about -$7.8M; EBITDA about -$7.8M). While losses are narrower versus FY2022 (net loss about -$17.5M) and improved from FY2023, the business still lacks commercial scale and remains structurally unprofitable, which keeps the income statement profile weak.

Balance Sheet

The balance sheet is conservatively levered, with essentially no debt in recent periods (debt-to-equity near 0), which reduces financial risk. Equity has risen meaningfully versus FY2024 (about $14.0M TTM vs. ~$2.0M FY2024), improving the capitalization base; however, returns remain deeply negative (TTM return on equity around -65%), reflecting ongoing losses and continued reliance on funding to sustain operations.

Cash Flow

Cash generation is a key pressure point: TTM operating cash flow is about -$7.9M and free cash flow about -$7.9M, indicating ongoing cash burn to fund operations. Cash burn improved versus FY2022 (free cash flow about -$12.3M), but free cash flow remains consistently negative and closely tracks net losses, leaving limited internal funding capacity.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-101.62K	-119.27K	-186.05K	-183.47K	-118.19K	-118.79K
EBITDA	-7.77M	-7.07M	-5.98M	-8.19M	-17.43M	-13.22M
Net Income	-7.82M	-7.19M	-6.17M	―	-17.55M	-13.34M
Balance Sheet
Total Assets	14.71M	13.53M	3.81M	8.89M	11.58M	14.58M
Cash, Cash Equivalents and Short-Term Investments	12.05M	10.79M	1.04M	5.36M	7.09M	7.84M
Total Debt	0.00	0.00	19.87K	94.49K	18.98K	99.32K
Total Liabilities	756.16K	1.08M	1.83M	1.84M	2.18M	1.53M
Stockholders Equity	13.95M	12.45M	1.98M	7.05M	9.39M	13.06M
Cash Flow
Free Cash Flow	-7.94M	-7.32M	-4.89M	-6.64M	-12.28M	-13.67M
Operating Cash Flow	-7.94M	-7.32M	-4.89M	-6.64M	-12.28M	-13.66M
Investing Cash Flow	0.00	0.00	0.00	0.00	-5.66K	-6.15K
Financing Cash Flow	18.59M	17.03M	592.03K	4.83M	11.63M	14.17M

Edesa Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDSA, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.35, and below the 200-day MA of 1.95, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 76.16 is Negative, neither overbought nor oversold. The STOCH value of 80.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EDSA.

Edesa Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	54 Neutral	$49.08M	-8.70	-32.92%	―	-44.31%	-34.17%
EDSA	52 Neutral	$19.03M	-1.99	-99.57%	―	―	30.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCP	45 Neutral	$14.47M	-1.12	-94.94%	―	―	49.10%
XTLB	39 Underperform	$6.12M	-6.83	―	―	―	65.45%
BIVI	38 Underperform	$10.11M	-0.26	-94.79%	―	―	84.44%

Edesa Biotech Corporate Events

Edesa Biotech Reports Positive Phase 3 Paridiprubart Results

On February 24, 2026, Edesa Biotech reported additional positive Phase 3 data for paridiprubart from a 278-patient study, showing a statistically significant reduction in adjusted 28-day mortality to 24% from 33% versus placebo across the full treatment population. Benefits were consistent across severity levels and comorbidities, with higher clinical improvement rates by Day 28 and a safety profile comparable to placebo, reinforcing the drug’s potential in critical care settings.

Exploratory analyses showed that in 174 non-ventilated patients, paridiprubart plus standard of care cut adjusted 28-day mortality to 15% from 23%, and mortality reductions of 30%-36% were observed in patients with pneumonia, acute kidney injury and sepsis. Building on these results, Edesa has filed provisional patents for using paridiprubart in these indications, while parallel government-funded trials and manufacturing scale-up support the company’s late-stage development and commercial-readiness strategy.

The most recent analyst rating on (EDSA) stock is a Sell with a $0.73 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.